Home  »  Finance  »  Kenox Pharmaceuticals announces successful completion of a pre-IND meeting with the US-FDA for its lead program KNX018 – a novel inhaled drug-device combination product as an adjunct sensitizer for radiation therapy in NSCLC patients

Kenox Pharmaceuticals announces successful completion of a pre-IND meeting with the US-FDA for its lead program KNX018 – a novel inhaled drug-device combination product as an adjunct sensitizer for radiation therapy in NSCLC patients

PRINCETON, N.J., Dec. 14, 2021 /PRNewswire/ — Kenox Pharmaceuticals Inc, a privately owned pharmaceutical company focused on respiratory drug products, has submitted Type B Pre-Investigational New Drug (IND) meeting request with the U.S. Food and Drug Administration (FDA) for its lead…

About the Author

has written 42014 stories on this site.

«
»
Copyright © 2010 Business and Corporate News.